Exchange Traded Concepts LLC Boosts Stock Holdings in Agenus Inc. (NASDAQ:AGEN)

Exchange Traded Concepts LLC lifted its stake in Agenus Inc. (NASDAQ:AGEN) by 52.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,543 shares of the biotechnology company’s stock after purchasing an additional 9,422 shares during the period. Exchange Traded Concepts LLC’s holdings in Agenus were worth $151,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets raised its stake in Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 84,477 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after acquiring an additional 4,134,232 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 720,629 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 123,058 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new position in Agenus in the second quarter valued at approximately $1,921,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Stock Down 0.2 %

Shares of NASDAQ:AGEN opened at $4.49 on Wednesday. The company has a 50-day moving average price of $5.15 and a 200 day moving average price of $9.25. Agenus Inc. has a 52 week low of $4.18 and a 52 week high of $19.69. The company has a market cap of $94.29 million, a P/E ratio of -0.34 and a beta of 1.37.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million during the quarter, compared to analysts’ expectations of $64.73 million. During the same period last year, the firm earned ($4.00) EPS. Analysts expect that Agenus Inc. will post -10.87 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Jefferies Financial Group reissued a “hold” rating and issued a $7.00 target price (up from $3.00) on shares of Agenus in a report on Friday, July 19th. B. Riley lowered their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $35.00 to $8.00 in a research note on Friday, July 19th. Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. Finally, StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.